EMN 2021 - 2nd European Myeloma Network Meeting (Virtual Meeting)
Mar 03 - Mar 06, 2021 | AmsterdamNetherlands
LARVOL is not affiliated with 2nd European Myeloma Network Meeting (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 19 abstracts linked to Trials
[VIRTUAL] HIGH LEVELS OF CIRCULATING PLASMA CELLS (CPC) ARE AN INDEPENDENT HIGH-RISK FEATURE BUT ARE MODULATED BY MINIMAL RESIDUAL DISEASE (MRD) NEGATIVITY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS TREATED WITH NOVEL AGENTS
[VIRTUAL] IMPACT OF GAIN AND AMPLIFICATION OF 1Q IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS RECEIVING CARFILZOMIBBASED TREATMENT IN THE FORTE TRIAL
[VIRTUAL] MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) AND NEXT-GENERATION SEQUENCING (NGS) IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (NDMM): RESULTS FROM THE FORTE TRIAL
[VIRTUAL] DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN TRANSPLANT- INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FRAILTY SUBGROUP ANALYSIS OF MAIA
[VIRTUAL] PREDICTORS OF EARLY RELAPSE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: INTEGRATED ANALYSIS OF BASELINE FEATURES AND ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY
[VIRTUAL] TREATMENT EMERGENT PERIPHERAL NEUROPATHY IN THE CASSIOPEIA TRIAL
[VIRTUAL] CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
[VIRTUAL] TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS
[VIRTUAL] TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM AN ONGOING PHASE 1 STUDY
[VIRTUAL] ON-DEMAND PLERIXAFOR FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA: A PRELIMINARY ANALYSIS OF THE OBSERVATIONAL STUDY MOZOBL06877
[VIRTUAL] IXAZOMIB-BASED INDUCTION FOLLOWED BY SINGLE-AGENT IXAZOMIB MAINTENANCE IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: UPDATED RESULTS OF THE EMN10-UNITO TRIAL
[VIRTUAL] DEPTH OF RESPONSE AND RESPONSE KINETICS OF ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA: IKEMA INTERIM ANALYSIS
[VIRTUAL] RECOVERY OF OCULAR EVENTS WITH LONGER-TERM FOLLOW-UP IN THE DREAMM-2 STUDY OF SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
[VIRTUAL] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN 55 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE—SUBGROUP ANALYSIS
[VIRTUAL] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) EXPOSED TO PRIOR ALKYLATOR THERAPY—SUBGROUP ANALYSIS